Therapeutic Suppression of Specific Immune Responses by Administration of Oligomeric Forms of Antigen of Controlled Chemistry
The method and construct used to reduce undesired antibody response in a mammal by administering a non-immunogenic construct of which contains at least two copies of a B cell membrane immunoglobulin receptor epitope bound to a pharmaceutically acceptable non-immunogenic carrier. This directly binds to the B cell membrane immunoglobulin receptors but fails to form an immunon. Description (Set) Proposed Use (Set) This invention is available for licensing for use in treatment of all diseases and conditions with the exception of cancer, antiphospholipid syndrome, xenografts, and lupus
Patent (Set) 7,083,959; 5,126,131; 5,370,871; 6,375,951; 6,340,460; 6,022,544
Patents:US 7,083,959
Inventor(s):
Dintzis, Renee Z.
Type of Offer:
Licensing
« More Pharmaceutical Patents